positive with all four antibodies. Some variability in the immunostaining could be observed depending on the antibody used. This was noticeable both for the number of positive cells within a section and for the intensity of staining. We therefore selected a panel of 17 tumour sections (nine were highly positive, three with medium to low staining and five with low to negative staining), which we analysed by polymerase chain reactionsingle-strand conformation polymorphism analysis (PCR-SSCP) for the presence of a p53 mutation at the molecular level. Mutations were identified in 15 cases. Therefore the proportion of p53-stained cells does not seem to be an exact representation of the number of cancer cells bearing a mutation within a tumour. A statistically significant correlation was observed between p53 expression, regardless of the number of positive antibodies, and grade III disease (P<0.0001), oestrogen (P<0.0001) or progesterone receptor negativity (P = 0.0061), increased Ki 67 index (P = 0.0018), epidermal growth factor receptor (EGFR) positivity (P = 0.0076) and aneuploidy (P = 0.037). No correlation was observed with tumour size or lymph node involvement. In univariate analysis p53 expression was not correlated with disease-free survival, in contrast to the classical prognostic parameters, which were statistically correlated. In this series p53 expression was not a marker of early recurrence.
The identification of biological and molecular parameters allowing discrimination between subsets of breast cancers is an important challenge for improved management of the disease. Currently, clinical parameters such as TNM staging, metastatic involvement of axillary lymph nodes and histological grading remain the major prognostic factors (Fisher et al., 1975; Contesso et al., 1987) . However, biological parameters such as hormone receptor status and DNA ploidy have also proven helpful (Clark et al., 1989; McGuire et al., 1990) . More recently, studies on alterations affecting oncogenes and anti-oncogenes have suggested that these may also become interesting prognostic indicators (Slamon et al., 1989; Gullick et al., 1990) .
Inactivation or abnormal expression of anti-oncogenes appears to play an important role in the genesis and/or progression of cancer. The wild-type p53 protein possesses growth-suppressing potential and acts as a cell cycle checkpoint, whereas its mutated counterpart either loses its antioncogene characteristics or acquires oncogenic potential (Lane & Benchimol, 1990; Kastan et al., 1992) . These properties, added to the observation by Nigro et al. (1989) that p53 could be mutated in a substantial proportion of colon carcinomas, quickly made this gene the most studied topic in human cancer. p53 turned out to be the most frequently altered gene in human tumours, since all the cancer types analysed to date have displayed p53 mutations, although at varying frequencies (Hollstein et al., 1991 ). An interesting characteristic of p53 mutations (reviewed in Caron de Fromentel & Soussi, 1992) lies in the increased stability of the mutated protein, whose half-life is increased by a factor of 10-20 as compared with the wild-type protein (Lane & Benchimol, 1990) . This leads to the accumulation of mutated p53 protein in the cell nucleus, which makes it detectable by standard immunostaining procedures (Lane & Benchimol, 1990 al., 1988; Davidoff et al., 1991a; Horak et al., 1991; Iwaha et al., 1991; Ostrowski et al., 1991; Barbareschi et al., 1992; Isola et al., 1992; Poller et al., 1992; Thor et al., 1992; Allred et al., 1993; Barnes et al., 1993; Silvestrini et al., 1993) . However, variations can be found from one study to another concerning the frequencies of positively stained tumours, which vary from 20 to 55%. Patterns of immunoreactivity also show some variability, since staining could either be purely nuclear or fully cytoplasmic (Horak et al., 1991) . It has, furthermore, been noticed that the frequency of p53 mutants detected by immunostaining is often twice as high as by polymerase chain reaction (PCR)-based methods such as single-strand conformation polymorphism (SSCP), denaturation gradient gel electrophoresis (DGGE) or chemical cleavage (Mazars et al., 1992) .
These elements led us to evaluate the detection of p53 accumulation in a series of breast tumours for which sections could be made from both frozen and formalin-fixed/paraffinembedded tissues. In the present work, we analysed p53 immunostaining using four monoclonal antibodies on frozen and/or fixed tissues, and calculated its prognostic significance. In 
Immunohistochemistry
The frozen sections were air dried for 10 min and fixed in acetone at 18°C for 10 min. The paraffin sections were pretreated three times by microwaving at 700 W in citrate buffer pH 6.2 for 15 min. After standard inhibition of endogenous peroxidase activity, staining of p53 protein was performed with the different monoclonal antibodies under the conditions detailed in Table I . Binding of the antibodies was detected by using the ABC immunoperoxidase system (Vectastain, Vector). All series included positive controls. Negative controls included substitution of monoclonal antibody by phosphate-buffered saline (PBS). All controls gave satisfactory results. In addition to p53 antibodies, immunohistochemistry was performed for most of the patients (see Table III (Jacquemier et al., 1986) . The p53 protein was revealed by a nuclear staining, and quantitated in terms of percentage of positive cells.
Flow cytometry
Tumour ploidy and S-phase were analysed by FACscan (Beckton Dickinson) on frozen-thawed fragments stained with propidium iodide. The coefficient of variation was below 5% for all statistical analyses.
PCR-SSCP analysis PCR conditions, pairs of primers used, and SSCP conditions were as previously described (Mazars et al., 1992) Correspondence between p53 antibody staining and PCR-SSCP analysis These differences between antibodies in the numbers of positive tumours and in the proportions of stained cells led (Table II) . Stained tissue sections were scraped, processed for DNA extraction and sequences within exons 4-9 of the p53 gene were amplified by PCR. Radiolabelled PCR fragments were subsequently analysed by SSCP and mutated DNA sequences identified because of their variant electrophoretic patterns. Although the method would not apply for exact quantification, we found that it could be helpful to estimate the ratio of mutated versus wild-type p53 sequence in a given DNA sample. To verify this, we performed a PCR-SSCP analysis on a cloned mutant p53 sequence serially diluted with a cloned wild-type sequence. As shown in Figure 1 , the relative intensities of the mutated and wild-type bands were proportional to the input of their templates. We then performed a PCR-SSCP analysis on 17 sections, of which nine were highly positive, three showed medium to low staining and five low to negative staining (Table II) . It is noticeable, however, that most sections displayed different intensities of staining depending on the antibody used (Figure 2 (Table III) . Interestingly, p53 positivity seemed to be dependent on the type of tumour tested, since only infiltrating ductal carcinomas stained positively, whereas tumours of other types scored negative. Statistically significant correlations were found with a number of parameters known to be associated with poor prognosis (Table III) . For instance, positive p53 reactivity was strongly correlated with grade III disease (P = 0.0001), loss of oestrogen receptor (P = 0.0001) or progesterone receptor (P = 0.0061) expression, positive Ki 67 staining (P = 0.0018) and EGFR expression (P = 0.0076). Less significant values were obtained with aneuploidy or lymphoid stromal reaction. These results indicate that positive p53 immunostaining is associated with highly proliferative or aggressive breast carcinoma showing most of the signs of aggressiveness. However, it is interesting to note that no association could be found with axillary lymph node involvement. These results were independent of the antibody used.
p53 expression and clinical evolution of the disease In order to assess the prognostic value of positive p53 immunostaining and compare it with that of usual markers of prognosis, we performed an univariate analysis (Table IV) . The results indicate that, in the presently studied set of patients, the classical prognostic parameters were correlated with disease-free survival such as tumour size (P= 0.043), nodal status (P = 0.0030), oestrogen receptor (P= 0.0108) and progesterone receptor (P = 0.011).
In contrast, histoprognostic grade and p53 staining were not correlated with disease-free survival for this short period of follow-up. This absence of correlation was observed whatever the antibody used.
Discussion
Abnormal expression of p53 protein has been widely studied in human breast cancer, and most investigators conclude an association with aggressive forms of the disease (Iwaya et al., 1991; Ostrowski et al., 1991; Isola et al., 1992; Thor et al., 1992) . However, important differences can be found from one study to another, the number of positively stained samples ranging from 22% to more than 50%. In the present study, we used a combination of four commercially available monoclonal antibodies to assess the accumulation of p53 protein in a series of 136 primary breast cancers. We observed 38% of the tumours staining positively with at least one antiserum. Numbers were lower when each antibody was considered individually, ranging from 17% to 30%. Our p53 ANTIBODIES numbers are in agreement with those reported by Thor et al. (1992) , but remain low compared with those reported by a number of other investigators (Cattoretti et al., 1988; Bartek et al., 1991; Horak et al., 1991) . Variations might reflect heterogeneity between the tested cohorts of tumours, as testified by the larger numbers of p53-positive cases observed in Li--Fraumeni patients compared with a population of sporadic breast cancers (Thor et al., 1992) , but technical conditions could also account for these disparities. In fact, the conditions of fixation (type of fixative and duration of the process) and antibody used have been shown to influence greatly the numbers of positive cases and the patterns of staining, such as the numbers of stained cells and cytoplasmic positivity (Bartek et al., 1990a, b) . Some of our own observations (data not shown), as well as variations in the proportions of tumour cells showing immunoreactivity when different antibodies were compared -some tumours could show 70 or 80% positive cells with a given MAb and be negative or weakly positive with another antiserum -confirm that p53 immunostaining depends greatly on the conditions and reagents used in the test. Our data indicate that using several antibodies in combination may reduce the extent of the variations. Results by Varley et al. (1991) and Allred et al. (1993) further support this observation.
These variations in staining patterns as well as reports on possible discrepancies between immunohistochemistry and analyses for mutations at the DNA level (Borresen et al., 1991; Thompson et al., 1992) led us to perform a comparative search for mutations in the p53 gene using PCR-SSCP on a selected set of p53-positive breast tumours. Our data suggest that there is a good overlap between the presence of a mutation at the DNA level and positive immunostaining in breast cancer since only 2/17 samples scored negative upon PCR-SSCP analysis. The correspondence might even be better given the fact that mutations may be missed by PCR-SSCP, as shown by some of our comparative tests with DGGE (C. Moyret, C. Theillet, L. Puig, J.P. Moles, G. Thomas & R. Hamelin, submitted). Therefore, the two tumours in which no mutation was detected despite the presence of positive staining may still bear a mutated p53 allele. If, according to the present data, positive immunostaining often corresponds to the presence of a mutation at the genetic level, the reverse is not always true. We used an inverse approach by testing by immunohistochemistry tumours which we had previously analysed for PCR-SSCP and found that most mutants presented p53 staining; only nonsense mutants were negative (J.P. Moles & C. Theillet, unpublished results). The next question we asked was if the number of cells stained with an anti-p53 antibody within a tumour section reflected the number of cells actually bearing a mutated p53 gene. As a matter of fact, a number of studies have shown that some breast tumours could present focal p53 staining corresponding to islets of p53-positive cells (Bartek et al., 1991; Davidoff et al., 1991b; Horak et al., 1991) . These results, added to some of our SSCP observations showing that the wild-type allele was frequently retained in tumours presenting mutated p53 sequences (Mazars et al., 1992) , suggested to us that the mutation might be present only in a fraction of the cancer cells forming these samples. Therefore, we wanted to verify if the proportions of cancer cells stained by immunohistochemistry were concordant with the signal ratio of mutated to wild-type sequences in the SSCP analyses, thus implying that p53 staining was indicative of the actual number of mutated cells. The results presented here indicate that while some concordance could be found some disparities also existed. Hence, we conclude that p53 staining is a somewhat imperfect reflection of the prevalence of p53 mutation and this is, in our mind, further supported by differences in staining when different antibodies are compared. Furthermore, heterogeneity in staining might be increased by physiological responses such as stabilisation of mild p53 in response to a genotoxic stress.
Positive p53 immunostaining has, in a number of reports, been correlated with factors associated with poor prognosis, early relapse or shortened disease-free survival (Thor et al., 1992; Allred et al., 1993) . Only two studies did not show similar correlations (Varley et al., 1991; Poller et al., 1992) . Most studies show a correlation in either monoparametric (Iwaya et al., 1991; Ostrowski et al., 1991; Isola et al., 1992; Thor et al., 1992) or multiparametric analysis. In our series such a correlation could not be observed. This could be attributed to a short follow-up. In contrast, most classical parameters, such as nodal status or oestrogen and progesterone receptors, were significantly correlated. This suggests that, in this series, p53 detected by immunohistochemistry is not indicative of early recurrence.
Despite the fact that immunostaining does not permit the detection of all mutations affecting p53 (nonsense mutations do not lead to p53 accumulation), recent reports showing the possibility of p53 staining in the absence of detectable mutations are an additional argument in favour of this method in the assessment of high-risk breast cancer patients. However, the variations in staining patterns and numbers of positive tumours one observed depending on the antibody and/or technical conditions used necessitates standardisation of the methods and reagents used in such studies.
